TherapeuticsMD financials
$2.04−2.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M | $64.9M | $49.6M | $16.1M | $16.8M | $19.4M |
| Gross profit | $3.0M | $1.8M | $1.3M | $68.6M | $1.2M | $48.9M | $43.3M | $13.4M | $14.1M | $15.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 98.0% | 45.5% | 75.4% | 87.2% | 83.0% | 84.3% | 78.4% |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M | -$155.5M | -$151.2M | -$130.2M | -$77.6M | -$90.3M |
| Net income | -$569.0K | -$2.2M | -$10.3M | $112.0M | -$172.4M | -$183.5M | -$176.1M | -$132.6M | -$76.9M | -$89.9M |
| Net margin | −18.8% | −123.9% | −789.4% | 160.1% | −6700.9% | −282.9% | −354.8% | −823.7% | −458.5% | −464.3% |
| Diluted EPS | $-0.05 | $-0.19 | $-0.99 | $11.96 | $-21.66 | $-33.50 | $-36.00 | $-29.50 | $-18.50 | $-23.00 |
| EBITDA | -$4.0M | -$5.6M | -$7.6M | $11.9M | -$78.8M | -$151.5M | -$149.8M | -$129.9M | -$77.4M | -$90.1M |
| Operating cash flow | $2.4M | $732.0K | -$48.1M | -$4.1M | -$142.7M | -$162.0M | -$166.6M | -$106.8M | -$76.2M | -$69.1M |
| Free cash flow | $2.4M | $732.0K | -$48.1M | -$4.1M | -$142.7M | -$162.2M | -$169.0M | -$107.0M | -$76.2M | -$69.5M |
| Diluted shares | 11.6M | 11.5M | 10.4M | 9.4M | 8.0M | 5.5M | 4.9M | 4.5M | 4.1M | 3.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.5M | $5.1M | $4.3M | $38.1M | $64.9M | $80.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $188.3M | $237.7M |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M | $181.6M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M | $305.6M |
| Shareholders' equity | $26.9M | $27.4M | $29.3M | $35.1M | -$93.6M | -$124.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology